Stockscreener 앱 받기
3.15
3.62%
0.11
전일 마감가:
$3.04
열려 있는:
$3.1
하루 거래량:
6.74M
Relative Volume:
1.78
시가총액:
$876.62M
수익:
-
순이익/손실:
$-241.99M
주가수익비율:
-3.355
EPS:
-0.9389
순현금흐름:
$-133.64M
1주 성능:
+13.72%
1개월 성능:
+3.62%
6개월 성능:
-30.00%
1년 성능:
+14.13%
1일 변동 폭
$3.025
$3.2002
1주일 범위
$2.67
$3.215
52주 변동 폭
$2.58
$6.55
사나 바이오테크놀로지 Stock (SANA) Company Profile
명칭
Sana Biotechnology Inc
전화
(206) 701-7914
주소
188 EAST BLAINE STREET, SUITE 350, SEATTLE
Compare SANA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SANA
Sana Biotechnology Inc
|
3.15 | 876.62M | 0 | -241.99M | -133.64M | -0.9389 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
사나 바이오테크놀로지 Stock (SANA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-24 | 개시 | Wedbush | Outperform |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-03-18 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-03-14 | 개시 | Jefferies | Buy |
| 2025-01-08 | 업그레이드 | TD Cowen | Hold → Buy |
| 2024-11-05 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-06-26 | 개시 | Rodman & Renshaw | Buy |
| 2024-01-16 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-09-25 | 개시 | JMP Securities | Mkt Outperform |
| 2023-09-05 | 개시 | Citigroup | Buy |
| 2023-08-14 | 개시 | TD Cowen | Market Perform |
| 2023-05-02 | 개시 | H.C. Wainwright | Neutral |
| 2021-03-01 | 개시 | BofA Securities | Buy |
| 2021-03-01 | 개시 | Goldman | Neutral |
| 2021-03-01 | 개시 | JP Morgan | Neutral |
| 2021-03-01 | 개시 | Morgan Stanley | Overweight |
모두보기
사나 바이오테크놀로지 주식(SANA)의 최신 뉴스
Sana Biotechnology Inc (SANA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Sana Biotechnology Inc (SANA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Sana Biotechnology Inc (SANA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Sana Biotechnology Inc (SANA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Sana Biotechnology Inc (SANA) Institutional Confidence - TradingKey
Sana Biotechnology Inc (SANA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Sana Biotechnology Inc (SANA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Sana Biotechnology Inc (SANA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Sana Biotechnology Inc (SANA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Sana Biotechnology, Inc. Stock 12‑Month Price Target Cut to $9.14, Implies 230% Upside - TradingView
Sana Biotechnology raises $69M through ATM share sale - MSN
SANA: Gene-modified islet and in vivo CAR T therapies advance toward pivotal trials and key data in 2024 - TradingView
Sana Biotechnology, Inc. - MLQ.ai
SANA SEC FilingsSana Biotechnology, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Sana Biotechnology | 4: Statement of changes in beneficial ownership of securities-Director Bilenker Joshua H. - Moomoo
Sana Biotechnology | 4: Statement of changes in beneficial ownership of securities-Director NELSEN ROBERT - Moomoo
Sana Biotechnology Shareholders Reelect Directors and Ratify Auditor - TipRanks
Sana Biotechnology (SANA) director awarded options for 90,000 shares at $2.96 - Stock Titan
Sana Biotechnology (SANA) director granted 90,000 stock options at $2.96 strike - Stock Titan
Director Michelle Seitz gets 90,000 Sana (SANA) stock options - Stock Titan
Sana Biotechnology (SANA) grants director 90,000 stock options at $2.96 - Stock Titan
Sana Biotechnology (SANA) director receives 90,000-share stock option grant - Stock Titan
Sana Biotechnology (SANA) director granted 90,000 stock options at $2.96 - Stock Titan
Sana (SANA) director awarded 90,000 stock options vesting in 2027 - Stock Titan
Sana Biotechnology (SANA) shareholders elect directors, ratify Ernst & Young LLP - Stock Titan
SANA Stock Chart | SANA BIOTECHNOLOGY INC (NASDAQ:SANA) - ChartMill
SANA: Hypoimmune cell therapy and in vivo CAR T trials to start this year, with data expected in 12 months - TradingView
SANA Stock Price, Quote & Chart | SANA BIOTECHNOLOGY INC (NASDAQ:SANA) - ChartMill
Law firm probes Sana Biotech officers for possible shareholder duty breaches - Pluang
Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire
Stream Sana Biotechnology's June investor talks live online - Stock Titan
Seattle InnoSana and Bothell I Following up with ZenLedger - The Business Journals
Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum - Quantisnow
Sana Biotechnology to Present at June 2026 Investor Conferences - The Manila Times
Sana Biotechnology to present updates at two major healthcare investor conferences in June 2026 - Pluang
RA Capital affiliates report 18.75M Sana Biotechnology shares (NASDAQ: SANA) - Stock Titan
Sana Biotechnology | SCHEDULE 13G: Others - Moomoo
Morgan Stanley Maintains Sana Biotechnology(SANA.US) With Buy Rating, Cuts Target Price to $3.07 - Moomoo
InvestingPro Fair Value spotted Sana Biotech overvaluation early By Investing.com - Investing.com Canada
Sana Biotech rises as Mayo Clinic partners for diabetes therapy - MSN
Sana Biotechnology Shares Fall on Sale of $69 Million in Shares Through At-The-Market Facility - Moomoo
Sana Biotechnology Raises $69 Million Through Equity Offering - TipRanks
Sana Biotechnology (SANA) sells 21.6M shares to raise about $69M - Stock Titan
Sana Biotechnology | 8-K: Current report - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Sana Biotechnology Raises $69 Million Through ATM Equity Offering - Moomoo
Sana Biotechnology raises $69 million through stock sale By Investing.com - Investing.com Australia
Sana Biotechnology raises $69 million through stock sale - Investing.com
Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through Its At-the-Market (ATM) Facility - 富途牛牛
Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs - The Manila Times
Sana presents preclinical data on in vivo CAR T therapy SG293 - Investing.com UK
사나 바이오테크놀로지 (SANA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):